Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers - Concepedia

Concepedia

Publication | Closed Access

Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers

66

Citations

9

References

2012

Year

Salyka Sengsayadeth, Madan Jagasia, Barbara Engelhardt, Adetola A. Kassim, Stephen A. Strickland, Stacey Goodman, Catherine Lucid, Cindy L. Vnencak‐Jones, John P. Greer, Bipin N. Savani

Bone Marrow Transplantation

Conventional MarkersOncogenic AgentMedicineGeneticsNatural SciencesBiomarker TargetMolecular BiologyHigh-risk Aml-cr1Cancer GenomicsCancer GeneticsGene ExpressionMolecular DiagnosticsMolecular Era

References

	Year	Citations

Page 1

Page 1